News release

JLL advises UCB on agreement to acquire a new leading-edge UK campus

JLL has advised UCB (a global biopharmaceutical company headquartered in Brussels, Belgium) on its agreement to acquire a new campus for its UK operations located in Windlesham, Surrey.

October 23, 2020

The campus will become home to one of UCB’s three global R&D hubs bolstering its cutting-edge R&D, early manufacturing and commercial operations in the UK.

JLL has advised UCB on its agreement to acquire a new campus for its UK operations supporting cutting-edge research and development, early manufacturing and commercialisation of medicines aiming to transform the lives of people living with severe immunological and neurological conditions.

The acquisition of the world-class site in Windlesham, Surrey is anticipated to be completed in November 2020.

The 47-acre (19 hectare) campus will be acquired by UCB from Eli Lilly and Company Limited and was formerly its second largest research site worldwide. Following completion of the acquisition, the site will undergo state-of-the-art refurbishment prior to UCB relocating from its current UK headquarters in Slough, Berkshire. This refurbishment will enable successful execution of UCB’s research plan to develop innovative treatments for patients including gene therapies and translational medicine, as well as development of UCB’s world-class antibody discovery platforms.

JLL acted on behalf of UCB.

About JLL

JLL (NYSE: JLL) is a leading professional services firm that specializes in real estate and investment management. JLL shapes the future of real estate for a better world by using the most advanced technology to create rewarding opportunities, amazing spaces and sustainable real estate solutions for our clients, our people and our communities. JLL is a Fortune 500 company with annual revenue of $18.0 billion in 2019, operations in over 80 countries and a global workforce of nearly 93,000 as of June 30, 2020. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit